Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,950.00
(
0.90%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,352.74
(
0.20%
)
News Focus
News Focus
Post# of 447733
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Biobillionair

Send PM Follow Ignore
Followers 232
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Biobillionair

Re: io_io post# 240804

Monday, 01/13/2020 10:25:31 PM

Monday, January 13, 2020 10:25:31 PM

Post# of 447733

I would say that's Shameless Pumping 101.



I would say you have no understanding of AMARIN IP or current case. Current case does not argue composition patents because there is no argument ... the generics would directly infringe on Vascepa composition patents...see stipulated facts. The composition patents are enough to bar launch of Vascepa composition in any indication.

Pumping is stretching truth beyond actual boarders... 10-4 patent stops composition similar to Vascepa according to claims, that’s call the law.

BB

If you're not good at being yourself, then maybe that's being yourself!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News